Recurrent Melanoma Suspended Phase 1 / 2 Trials for Dabrafenib (DB08912)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Suspended1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01902173Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV CancerTreatment